Summary:
A phase 3 multi-center, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain.
Qualified Participants Must:
• 18-49 years of age
•
Diagnosed up to 10 years before screening
•
BMI greater than 17
Has not had a hysterectomy
•
Has not had bilateral oophorectomy
•
Has not had any major abdominal surgery
Qualified Participants May Receive:
High Quality Medical Care
Study Medication
$100.00 per visit for up to 16 visits
DXA Scan
Mammogram if >12 months since last screening
Transvaginal Ultrasound if required
Lab work